Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 25:9:892335.
doi: 10.3389/fcvm.2022.892335. eCollection 2022.

Etiology and Management of Dyslipidemia in Patients With Cancer

Mikhail de Jesus  1 , Turab Mohammed  1 , Meghana Singh  1 , John G Tiu  2 , Agnes S Kim  2
Affiliations
Review

Etiology and Management of Dyslipidemia in Patients With Cancer

Mikhail de Jesus et al. Front Cardiovasc Med. .

Abstract

Patients with cancer are now living longer than ever before due to the growth and expansion of highly effective antineoplastic therapies. Many of these patients face additional health challenges, of which cardiovascular disease (CVD) is the leading contributor to morbidity and mortality. CVD and cancer share common biological mechanisms and risk factors, including lipid abnormalities. A better understanding of the relationship between lipid metabolism and cancer can reveal strategies for cancer prevention and CVD risk reduction. Several anticancer treatments adversely affect lipid levels, increasing triglycerides and/or LDL-cholesterol. The traditional CVD risk assessment tools do not include cancer-specific parameters and may underestimate the true long-term CVD risk in this patient population. Statins are the mainstay of therapy in both primary and secondary CVD prevention. The role of non-statin therapies, including ezetimibe, PCSK9 inhibitors, bempedoic acid and icosapent ethyl in the management of lipid disorders in patients with cancer remains largely unknown. A contemporary cancer patient needs a personalized comprehensive cardiovascular assessment, management of lipid abnormalities, and prevention of late CVD to achieve optimal overall outcomes.

Keywords: cancer; cancer survivor; cardiovascular risk reduction; cholesterol; dyslipidemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The medical journey of cancer survivors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mattiuzzi C. Cancer statistics: a comparison between World Health Organization (WHO) and Global Burden of Disease (GBD). Eur J Public Health. (2020) 30:1026–7. 10.1093/eurpub/ckz216 - DOI - PubMed
    1. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti D, Jiang C, et al. . A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. (2019) 40:3889–97. 10.1093/eurheartj/ehz766 - DOI - PMC - PubMed
    1. Aparecida Silveira E, Vaseghi G, de Carvalho Santos AS, Kliemann N, Masoudkabir F, Noll M, et al. . Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: a Scoping Review of the Pathophysiology and Pharmacological Treatments. Int J Mol Sci. (2020) 21:E9042. 10.3390/ijms21239042 - DOI - PMC - PubMed
    1. Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardio-Oncol Lond Engl. (2021) 7:14. 10.1186/s40959-021-00101-2 - DOI - PMC - PubMed
    1. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. . The cancer patient and cardiology. Eur J Heart Fail. (2020) 22:2290–309. 10.1002/ejhf.1985 - DOI - PMC - PubMed